

Understanding the benefits of being vaccinated against chikungunya virus



What is IXCHIQ used for?

IXCHIQ is a vaccine for use in individuals 18 years of age and older to help protect against chikungunya virus disease.

- You should still protect yourself from mosquito bites even if you have received the IXCHIQ vaccine
- IXCHIQ may not fully protect everyone who gets the vaccine
- IXCHIQ does not protect against other diseases transmitted by mosquitoes

This vaccine is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies.

You should not get IXCHIQ if you:

- Have a weakened immune system due to certain conditions or therapy
- Have ever had a severe allergic reaction to any of the ingredients in the vaccine

IXCHIQ is not approved for use in children below the age of 18 years.



Why get vaccinated?

Chikungunya vaccine can help protect against chikungunya disease.

Chikungunya is a disease transmitted by mosquitoes spreading the chikungunya virus, CHIKV, which is found in the subtropical regions of the Americas, Africa, Southeast Asia, India, and the Pacific Region. As of late 2020, outbreaks of chikungunya in the Americas have resulted in an estimated 3 million cases. Since 2012, the virus has moved into European territories, with 13 EU countries reporting 2,616 travel-related chikungunya cases.

All travelers to endemic regions are at risk for infection. Health authorities warn of a high risk for chikungunya virus as the mosquitoes that spread the disease begin to establish in new areas. The impact is likely the greatest for populations naive to the virus, such as travelers who have returned from endemic areas. It is recommended that travelers prevent mosquito bites by wearing repellent for 3 weeks after their trip.

The majority of CHIKV-infected people (up to 97% in some studies) develop symptoms characterized by acute onset of fever and severe pain in multiple joints. Acute symptoms typically resolve within 7 to 10 days, but some symptoms, in particular the joint pain associated with chikungunya, is often debilitating and may last for months to years in some people (up to 43%). "Chikungunya" means "to become contorted" in the African Kimakonde language, describing the effects of chikungunya-related persistent joint pain.

There is no specific treatment for chikungunya. The clinical management includes addressing fever and joint pain with anti-inflammatory agents and painkillers, drinking plenty of fluids, and general rest. Talk to a healthcare provider about any medical conditions you think you may have.



IXCHIQ vaccine

IXCHIQ is a vaccine approved for the prevention of disease caused by CHIKV in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.

Data from clinical trials showed that IXCHIQ stimulated the development of antibodies that neutralize the chikungunya virus in 98.9% of adults at 28 days post vaccination and sustained levels of antibodies for up to 6 months.

In clinical studies, the most common solicited injection site adverse reaction (>10%) was tenderness (10.6%). The most common solicited systemic adverse reactions (>10%) were headache (31.6%), fatigue (28.5%), and muscle pain (23.9%). In some cases, joint pain (17.2%), fever (13.5%), nausea (11.2%), rash (2.3%), and vomiting (1.9%) may occur.

IXCHIQ may not protect everyone who gets the vaccine. You should still protect yourself from mosquito bites even if you have received the IXCHIQ vaccine. Follow precautions to reduce exposure to mosquito bites (adequate clothing, use of repellents, mosquito nets).

Please see full [Prescribing Information](#) for IXCHIQ.



What if there is a serious problem?

Contact your healthcare provider right away if you get any symptoms after receiving IXCHIQ that concern you.

Tell your healthcare provider if you have any of the following problems because these may be signs of an allergic reaction: difficulty breathing, hoarseness, wheezing, hives, dizziness, weakness, or fast heartbeat.

To report suspected adverse reactions, contact Valneva USA Inc. at **1-844-349-4276** or VAERS at **1-800-822-7967** or <http://vaers.hhs.gov>



How can I learn more?

- Ask your healthcare provider
- Consult current national and international advisories regarding prevalence of chikungunya virus in specific locations
- Visit the US Centers for Disease Control and Prevention (CDC) and the Pan American Health Organization (PAHO)/World Health Organization (WHO) websites:



[Scan or click to visit the CDC chikungunya website](#)



[Scan or click to view the PAHO/WHO chikungunya fact sheet](#)



What warnings should I know about IXCHIQ?

- IXCHIQ can cause allergic reactions. Tell your healthcare provider immediately if you experience difficulty breathing, hoarseness, wheezing, hives, dizziness, weakness, or fast heartbeat
- IXCHIQ may cause severe or prolonged chikungunya-like side effects. Tell your healthcare provider about any side effects you experience
- Chikungunya virus can be passed from a pregnant individual to an unborn baby. It is not known if the vaccine virus can be transmitted from a pregnant individual to the fetus or newborn and cause adverse reactions
- Fainting can occur with administration of IXCHIQ
- Vaccination with IXCHIQ may not protect all who receive the vaccine. Continue to use methods to protect against mosquito bites after vaccination

What should I tell my healthcare provider?

It is very important to tell your healthcare provider if you:

- Have had an allergic reaction to any ingredient of IXCHIQ
- Have a bleeding disorder or are on a blood thinner
- Have a weakened immune system due to a condition or therapy
- Are or may be pregnant or are breastfeeding
- Currently have any illness with a fever of more than 38.0°C (100.4°F)
- Take any medicines, even those you can buy over the counter

What are the side effects of IXCHIQ?

The most common side effects are headache, fatigue, muscle pain, joint pain, fever, tenderness at the injection site, and nausea.

You are encouraged to report suspected adverse reactions to Valneva at **1-844-349-4276** or VAERS at **1-800-822-7969** or <http://vaers.hhs.gov>

For more information on IXCHIQ® (chikungunya vaccine, live), particularly details on safety, please visit IXCHIQhcp.com/PI or contact your healthcare provider.

Please see full [Prescribing Information](#) for IXCHIQ.